echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > BMC Gastroenterology: Serum hemolytic phospholipidase self-secretion protein (ATX) and hemolytic phospholipid acid (LPA) can be used as potential biomarkers for the diagnosis of pancreatic cancer

    BMC Gastroenterology: Serum hemolytic phospholipidase self-secretion protein (ATX) and hemolytic phospholipid acid (LPA) can be used as potential biomarkers for the diagnosis of pancreatic cancer

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent decades, early diagnosis and improved treatment have improved survival rates for many cancers.
    , pancreatic cancer (PC) remains one of the deadliest cancers, and its prognosmation is still poor.
    in patients with removable tumors, the PC's five-year survival rate ranged from 15% to 20%.
    5-year survival rate was close to 0% for those with pCs that showed unsealable tumors and distant metastasis.
    poor prognosis and low survival rates are mainly due to delays in diagnosis due to the lack of identifiable symptoms and early detection markers.
    , there is an urgent need for new biomarkers that can detect PCs early and reduce the possibility of transfer.
    hemolytic phospholipase self-secretion protein (ATX) and its product hemolytic phospholipid acid (LPA) play a vital role in the progression of disease in PC patients and is associated with an increase in the incidence of several cancers.
    in vitro and in vivo have shown that elevated ATX-LPA signal transductivity activity may help cancer progress and begin.
    , however, it is not clear whether plasma ATX and LPA can act as diagnostic biomarkers for PCs.
    study, researchers assessed the potential of plasma LPA and ATX as biomarkers of cancer.
    researchers obtained serum from 114 PC patients, 120 healthy volunteers and 4 patients with benign pancreatic disease, and conducted ELISA tests to assess ATX, LPA and CA19-9 levels.
    then perform a statistical analysis.
    results showed that serum ATX, LPA and CA19-9 levels were significantly higher in PC patients than in BPD patients or HVs (p .lt;0.001).
    LPA sensitivity in identifying early PCs was 91.74 percent and ATX specificity was 80 percent.
    at ATX, LPA, and CA19-9 levels were significantly higher in early PC patients than in BPD and HV patients.
    by adding ATX and LPA, the diagnostic efficacy of CA19-9 on PCs is significantly enhanced (p s 0.0012).
    this study has shown that LPA and ATX levels and CA19-9 level measurements of patients can be used for early detection and diagnosis of PCs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.